Video

Episode 5 - Setting the Tone: Current Therapeutic Goals

Appropriately managing the suite of cardiometabolic disorders has substantial clinical implications for cardiovascular health and prevention of cardiovascular disease (CVD). In the case of diabetes, dyslipidemias, and hypertension, achieving the goals of HbA1c <7%, LDL cholesterol <100 mg/dL, and blood pressure <140/90 sets the patient up with significant cardiovascular benefits, such as the prevention of downstream CVD, heart attack, heart failure, or stroke. Although there has always been a “disconnect” between what is known and what is actually done, on both clinician and patient levels, and at times, compromises have to be made to individualize treatments, there is still an awareness of the importance of managing the individual components of cardiometabolic disorders aggressively and effectively.


Related Videos
Mike Fazio, Navista, Cardinal Health
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Jaime Almandoz, MD, MBA
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Leigh Maria Ramos-Platt, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo